Latest From Biotech Now

San Francisco Chronicle: High drug co-pays deny needed treatments

Jim Greenwood

Today, the San Francisco Chronicle published an op-ed that I wrote on the importance of ensuring access to treatments for debilitating diseases that are saving millions of patients from pain and possible death. Patients rightly expect their health insurance plan to cover the best medicines based on their unique needs, at an out-of-pocket cost that makes these therapies accessible. Insurance companies and their allies, seeking to deflect blame for increased premiums at a time of Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Jim Murray Closes BIO LBS with Memorable Keynote

LBS-graphic-200x100 copy

“We need to learn how to feed the world better,  We cannot feed the world using organic or hunter-gatherer technologies.” – Dr. Jim Murray In his closing Keynote, Dr. James Murray, Professor Animal Science and Population Health at the University of California at Davis reminded attendees how vital animal biotechnology will be in helping to feed a rapidly growing population. Dr. Murray opened by commenting that one child dies every 5 seconds because of hunger. “This Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Tekmira Pharmaceuticals Ebola Drug Gets Nod From FDA

BIF_logo

The U.S. Food and Drug Administration has authorized Canada’s Tekmira Pharmaceuticals to provide an experimental drug to people with confirmed or suspected Ebola virus infections, according to an article in The Wall Street Journal. “Our TKM-Ebola drug supplies are limited, but we will continue to help where we can,” Tekmira Chief Executive Mark J. Murray said in a press release. The drug is still in clinical testing to assess whether it is safe and effective. BIO Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

FierceBiotech Names 2014 Fierce 15

FierceBiotech

FierceBiotech released their much-anticipated 2014 Fierce 15 list today, their annual list of private biotech upstarts to watch. We’ll be hearing from three of them at next month’s BIO Investor Forum, October 7-8 in San Francisco: Adaptimmune and Sutro Biopharma will be making company presentations, and Editas Medicine CEO Katrine Bosley will participate as a panelist in one of our therapeutic workshops, Gene Therapy Ascending? Today’s Advancements Over Past Hurdles. Here’s the scoop on each, Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Detailed Report Examines the Crucial Role of Patents in Genetic Testing

shutterstock_27291016

In The Critical Role of Patents in the Development, Commercialization, and Utilization of Innovative Genetic Diagnostic Tests, Professor Holman argues that advocates for weakening patent protection have fundamental misconceptions on the role of patents in genetic testing. Opponents assume that patents negatively impact patient access to genetic diagnostic testing. They believe that patents inhibit research that could lead to new or improved versions of genetic tests, and that patent holders charge higher prices as exclusive Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , ,